University of California, Los Angeles (UCLA), Health Sciences

ACTG Launches Clinical Trial Testing Treatment for COVID-19

Study will Evaluate Hydroxychloroquine+Azithromycin among Adults with Mild to Moderate COVID-19 in the United States


Newswise — Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2). There is currently no approved vaccine or therapeutic to prevent or treat COVID-19, which has been spreading worldwide since cases were first reported in December 2019 in Wuhan, Hubei Province, China. For information about enrolling in the trial, please email [email protected]

“There is an urgent public health need to rapidly evaluate interventions to treat COVID-19, which has emerged as a global pandemic in recent months,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “Well-designed trials are needed to evaluate whether drugs that have been studied and used over many years to treat other conditions are effective against COVID-19. ACTG’s history of implementing a wide variety of clinical trials over the last 33 years positions us well to quickly execute this clinical trial and help determine whether hydroxychloroquine and azithromycin may be an effective treatment for COVID-19.” 

ACTG is conducting this double-blind, placebo-controlled, randomized phase 2b clinical trial at 31 of its U.S.-based sites (the list can be accessed here) and will enroll approximately 2,000 adults with COVID-19. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, which also funds the ACTG. Participants will be randomized to orally receive one of two regimens. The first arm will receive a loading dose of hydroxychloroquine (400 mg twice a day on the first day), followed by 200 mg twice a day for six days, plus 500 mg of azithromycin on the first day, followed by 250 mg every day for four days. The second arm will receive matching placebos.

In order to qualify for the study, participants must have tested positive for SARS-CoV-2 infection in the outpatient setting and be experiencing at least one of the following symptoms: fever, cough, or shortness of breath. Eligible participants include people living with HIV, women who are pregnant, and those currently breastfeeding.

ACTG 5395 is being led by protocol chair Davey Smith, M.D. of the University of California, San Diego, along with David Wohl, M.D. of the University of North Carolina and Kara W. Chew M.D., M.S. and Eric S. Daar, M.D. of the University of California, Los Angeles.  

“Because the COVID-19 pandemic has been particularly devastating for people who are older and have underlying health issues, it is our goal that at least half of study participants will be members of these high-risk groups,” said Dr. Smith. “By ensuring meaningful representation of individuals who are 60 years and older or immunocompromised and those with chronic lung, kidney, and liver disease, severe obesity, hypertension, or diabetes, we are hopeful that we will gain important insights that will directly impact care for people with COVID-19.” 

As of May 14, 2020, the World Health Organization (WHO) has reported 4,218,212 cases and 290,242 related deaths worldwide. The United States became the epicenter of the epidemic on March 26, 2020, reporting more cases than any other country worldwide. As of May 13, 2020, the Centers for Disease Control and Prevention (CDC) has reported 1,364,061 cases and 82,246 related deaths in the United States. 

Hydroxychloroquine is currently approved for malaria treatment and prevention, as well as for the treatment of autoimmune conditions, including rheumatoid arthritis and lupus. Azithromycin is currently approved to treat bacterial infections, including sinusitis, community-acquired pneumonia, urethritis/cervicitis, pharyngitis, and acute exacerbations of COPD. While there has been some evidence that this drug combination may decrease viral loads among people with COVID-19, large, well-controlled clinical trials are needed to determine its true efficacy. The ACTG, with its ability to use existing sites and staff to rapidly conduct trials, is ideally positioned to conduct a major clinical trial among patients with COVID-19 (who currently have no proven treatment options) during this pandemic. 

For more information about ACTG 5395, visit or using study identifier NCT04358068.


About the AIDS Clinical Trials Group

Founded in 1987, the AIDS Clinical Trials Group (ACTG) is the world’s largest and longest established HIV research network. The ACTG conducts groundbreaking studies to improve the treatment of HIV and its complications, reduce new infections and HIV-related illness, and advance new approaches to prevent, treat, and ultimately cure HIV in adults and children. ACTG investigators and research units in 12 countries serve as major resources for HIV/AIDS research, treatment, care, and training/education in their communities. ACTG studies have helped establish current paradigms for managing HIV disease, and have informed HIV treatment guidelines, resulting in dramatic decreases in HIV-related mortality worldwide.



# # #



Filters close

Showing results

110 of 5402
Newswise: Palisades Medical Center COVID-19 Vaccine Efforts Support Community Health
Released: 14-Apr-2021 4:20 PM EDT
Palisades Medical Center COVID-19 Vaccine Efforts Support Community Health
Hackensack Meridian Health

Radames and Ana Arocho were all smiles when they arrived on the white school bus, and their enthusiasm was contagious.

Released: 14-Apr-2021 3:10 PM EDT
Most young people eager for COVID-19 vaccine, poll shows
Michigan Medicine - University of Michigan

As older teens and young adults become eligible for COVID-19 vaccination across the country, and younger teens await their turn, new survey data suggest a strong readiness that has grown since fall. But just as with older generations, a shrinking but still sizable minority of people age 14 to 24 say they’re not willing to get vaccinated, or that their decision will depend on safety.

Newswise: 261790_web.jpg
Released: 14-Apr-2021 12:10 PM EDT
A novel, quick, and easy system for genetic analysis of SARS-CoV-2
Osaka University

SARS-CoV-2 is the virus responsible for the COVID-19 pandemic.

Newswise: COVID-19 Mortality Rates in Los Angeles County Higher in Communities with Poor Air Quality
Released: 14-Apr-2021 12:05 PM EDT
COVID-19 Mortality Rates in Los Angeles County Higher in Communities with Poor Air Quality
UCLA Fielding School of Public Health

A research project led by the UCLA Fielding School of Public Health has found that Los Angeles County neighborhoods with poor air quality had the highest death rates from the pandemic.

Released: 14-Apr-2021 10:05 AM EDT
Grant accelerates McMaster University, SQI Diagnostics effort to move infection testing innovation from lab to market
McMaster University

A new grant is helping McMaster University engineers and a Toronto precision-medicine diagnostics company to get infection-testing technology to market while generating opportunities for students.

Newswise: Suppression of COVID-19 Waves Reflects Time-Dependent Social Activity, Not Herd Immunity
Released: 14-Apr-2021 10:05 AM EDT
Suppression of COVID-19 Waves Reflects Time-Dependent Social Activity, Not Herd Immunity
Brookhaven National Laboratory

Scientists developed a new mathematical model for predicting how COVID-19 spreads, accounting for individuals’ varying biological susceptibility and levels of social activity, which naturally change over time.

14-Apr-2021 9:00 AM EDT
Lower COVID-19 rates seen in US states with higher adherence to mask wearing

New evidence supports mask wearing in public as key to reducing spread of COVID-19

Newswise: So You Got Vaccinated Against COVID-19. Now What?
Released: 14-Apr-2021 8:05 AM EDT
So You Got Vaccinated Against COVID-19. Now What?
Michigan Medicine - University of Michigan

A slightly lighthearted guide to post-vaccination life, including how to help others who haven't gotten vaccinated yet.

Showing results

110 of 5402